IP Library Granted Patent US 9,512,230
Granted Patent B2
US 9,512,230 · App. 14/375,503 · Granted Dec 6, 2016

Transcription units and the use thereof in expression vectors

Inventors: Alexandre Fontayne (La Madeleine, FR); Francois Coutard (Ales, FR)
Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
C07K16/2887C07K16/34C12N15/85C12N2830/007C12N2830/15C12N2830/42C12N2830/60C12N2830/85
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,512,230
App. No.
14/375,503
Granted
Dec 6, 2016
Kind
B2
Abstract

Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium.

Claims (36)

1. A transcription unit comprising a polynucleotide comprising a sequence selected from the group consisting of:

(a) the sequence SEQ ID NO: 21, comprising:

(i) a hCMVie virus enhancer consisting of nucleotide sequence SEQ ID NO: 1 and possessing an activity of transcription activation,

(ii) a promoter region of B-actin consisting of nucleotide sequence SEQ ID NO: 3 and possessing a promoter activity, and

(iii) a regulatory region R of 5′ Long Terminal Repeat (LTR) of the HTLV-1 virus consisting of nucleotide sequence SEQ ID NO: 4 and having properties of stabilization of mRNA and a translation facilitator;

(b) the sequence SEQ ID NO: 22, comprising:

(i) a hCMVie virus enhancer consisting of nucleotide sequence SEQ ID NO: 1 and possessing an activity of transcription activation,

(ii) a promoter region of R-actin consisting of nucleotide sequence SEQ ID NO: 3 and possessing a promoter activity, and

(iii) a 5′ Untranslated Region (UTR) of a NF-KB Repressing Factor (NRF) gene consisting of nucleotide sequence SEQ ID NO: 5 and having properties of stabilization of mRNA and a translation facilitator;

(c) the sequence SEQ ID NO: 23, comprising:

(i) a hCMVie virus enhancer consisting of nucleotide sequence SEQ ID NO: 1 and possessing an activity of transcription activation,

(ii) a promoter region of R-actin consisting of the nucleotide sequence SEQ ID NO: 3 and possessing a promoter activity, and

(iii) a 5′ UTR region of an eukaryotic Initiation Factor 4GI (eIF4GI) gene consisting of nucleotide sequence SEQ ID NO: 6 and having properties of stabilization of mRNA and a translation facilitator;

(d) the sequence SEQ ID NO: 24, comprising:

(i) a hCMVie virus enhancer consisting of nucleotide sequence SEQ ID NO: 1 and possessing an activity of transcription activation,

(ii) a promoter region of R-actin consisting of the nucleotide sequence SEQ ID NO: 3 and possessing a promoter activity, and

(iii) a 5′ UTR region consisting of sequence SEQ ID NO: 7 and having properties of stabilization of mRNA and a translation facilitator;

(e) the sequence SEQ ID NO: 25, comprising:

(i) a hCMVie virus enhancer consisting of nucleotide sequence SEQ ID NO: 1 and possessing an activity of transcription activation,

(ii) a promoter region of B-actin consisting of nucleotide sequence SEQ ID NO: 3 and possessing a promoter activity, and

(iii) a 5′ UTR region consisting of sequence SEQ ID NO: 8 and having properties of stabilization of mRNA and a translation facilitator;

(f) the sequence SEQ ID NO: 26, comprising:

(i) a hCMVie virus enhancer consisting of nucleotide sequence SEQ ID NO: 1 and possessing an activity of transcription activation,

(ii) a promoter region of B-actin consisting of nucleotide sequence SEQ ID NO: 3 and possessing a promoter activity, and

(iii) a 5′ UTR region consisting of sequence SEQ ID NO: 9 and having properties of stabilization of mRNA and a translation facilitator; and

(g) the sequence SEQ ID NO: 27, comprising:

(i) a hCMVie virus enhancer consisting of nucleotide sequence SEQ ID NO: 1 and possessing an activity of transcription activation,

(ii) a promoter region of B-actin consisting of nucleotide sequence SEQ ID NO: 3 and possessing a promoter activity, and

(iii) a 5′ UTR region consisting of sequence SEQ ID NO: 10 and having properties of stabilization of mRNA and a translation facilitator.

2. The transcription unit according to claim 1 , wherein said polynucleotide comprises the nucleotide sequence of SEQ ID NO: 25, wherein said transcription unit, when expressed in a cell or cell line, is capable of producing a volume-based production of a protein of interest that is greater than that obtained with a transcription unit consisting of a combination of said CMV enhancer together with said promoter region of β-actin.

3. An expression vector comprising at least one transcription unit as defined according to claim 1 and at least one cloning site allowing integration of a nucleic acid coding for a protein of interest.

4. An expression vector comprising at least one transcription unit as defined according to claim 1 and at least one site for site-specific recombination allowing integration of a nucleic acid coding for a protein of interest.

5. The expression vector according to claim 3 , further comprising a eukaryotic resistance gene, a bacterial resistance gene, a bacterial replication origin and a unit dedicated to gene amplification.

6. The expression vector according to claim 3 , wherein said protein of interest is selected from the group consisting of the proteins participating in coagulation, immunoglobulins, cytokines, hormones, growth factors or complement factors and any fusion protein.

7. A host cell comprising an expression vector as defined in claim 3 .

8. The host cell according to claim 7 , wherein said host cell is a CHO-S, a CHO, or an HEK cell line.

Assignments (3)
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Apr 3, 2023
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 063237/0439 →
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Sep 21, 2022
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 061493/0885 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2014
From: FONTAYNE, ALEXANDRE; COUTARD, FRANCOIS
To: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 033776/0149 →
Priority Claims (1)
FR 12 51185 · Feb 8, 2012 · national
Continuity (1)
Related Publication 20150072368A1 · Mar 12, 2015